So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development
- 11 August 2020
- journal article
- review article
- Published by Elsevier BV in Vaccine
- Vol. 38 (41), 6381-6387
- https://doi.org/10.1016/j.vaccine.2020.08.017
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 36 references indexed in Scilit:
- A Short History of VaccinationPublished by Elsevier BV ,2018
- Vaccine SafetyPublished by Elsevier BV ,2017
- WHO R&D Blueprint: a global coordination mechanism for R&D preparednessThe Lancet, 2017
- Ethical Rationale for the Ebola “Ring Vaccination” Trial DesignAmerican Journal of Public Health, 2016
- Strategies for addressing vaccine hesitancy – A systematic reviewVaccine, 2015
- Design, recruitment, and microbiological considerations in human challenge studiesThe Lancet Infectious Diseases, 2015
- Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012Vaccine, 2014
- Risk in Vaccine Research and Development QuantifiedPLOS ONE, 2013
- Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccineCurrent Opinion in HIV and AIDS, 2010
- Ethics of vaccine researchNature Immunology, 2004